Tag: API

The Active Pharmaceutical Ingredient (API) is the part of any drug that is active. Some drugs, such as combination therapies, have multiple active ingredients to treat different diseases. While production of APIs has traditionally been done by the pharmaceutical companies themselves in their home countries, in recent years many corporations have opted to send manufacturing overseas to cut costs. This has caused significant changes to how these drugs are regulated, with more rigorous guidelines and inspections put into place.
All drugs are made up of two core components: the API, which is the central ingredient, and the excipient, the substance inside the drug that helps deliver the medication to your system. Excipients are inactive substances, such as mineral oil, and not chemically active.
Manufacturers use certain standards to determine how strong the API is in each drug. However, the standard can vary widely from one brand to another. One brand might use one test, another a different one.

Chugai Pharmaceutical to Construct a New Facility for API

Chugai Pharmaceutical Co., Ltd. (hereafter, “Chugai”) announced today the decision to construct a new manufacturing building for active pharmaceutical ingredients (APIs) for clinical studies in Fujied...

CPI Partenrs with GSK and AZ to Create New Site

GSK, AstraZeneca, and GEA join resources to create a site in the UK for developing small-scale oral solid dosage APIs. CPI is collaborating with partners GSK and AstraZeneca to establish a bespoke,...

WuXi STA Passed First GMP Inspection by MPA

STA Pharmaceutical Co., Ltd., – a subsidiary of WuXi AppTec – announces that its new drug product manufacturing facility in Shanghai Pilot Free Trade Zone has passed its first GMP inspection by the Eu...

SP Scientific Announced First New Advanced Freeze Dryers

The LyoConstellation series allows the development of highly aggressive cycles and the mapping of the furthest reaches of theoretical design space for a formulation. SP Scientific has announced the...

FDA Commented Recalling Lots of Blood Pressure Drugs

The US agency has said a problem with the manufacturing process is the likely source of contaminants. The recall of hundreds of lots of contaminated blood pressure drugs last summer has been the su...

FDA’s Update on Impurity in API Investigation

The investigation into the root cause of the NDMA impurity found in API is still ongoing, but the agency believes the impurities may be caused by specific chemicals and reaction conditions in manufact...

Olon Acquire Capua BioServices

Olon S.p.A., a world leading Active Pharmaceutical Ingredients (API) contract development and manufacturing organization (CDMO) and generics supplier, announced today the acquisition of Capua BioServi...

Particle Sciences Launches Nanomilling Feasibility Program

Advanced formulation techniques such as nanomilling may provide an excellent route to improved bioavailability and enhanced therapeutic effect. CDMO, Particle Sciences, a Lubrizol LifeSciences comp...

Alternative Technologies of Removing Catalysts from API

As the pharmaceutical industry has changed and grown in the last two decades, there are increasing concerns about the safe handling of active pharmaceutical ingredients (APIs)— particularly in the pro...

IMCoPharma Registrates APIs in Uzbekistan

IMCoPharma’s regulatory team have recently completed the registrations of several APIs in Uzbekistan. Namely these are Calcium chloride dihydrate, Magnesium chloride hexahydrate, Potassium chloride, M...

Novacap consolidates its CDMO subsidiaries to form SEQENS

Novacap, a global player in the pharmaceutical synthesis and specialty ingredients announced that it will combine its contract development and manufacturing organization subsidiaries.

AGC buys API manufacturer from Boehringer Ingelheim

AGC, a world-leading manufacturer of glass, chemicals and high-tech materials, has announced that it has entered into an agreement with Boehringer Ingelheim to acquire Malgrat Pharma Chemicals.

SID&GP to held a workshop on GMP requirements for API manufacturing

On 20-21 December, the State Institute of Drugs and Good Practices (FSI "SID&GP") jointly with Pharmstrategy Ltd. will held an open expert-advisory workshop "Requirements and Application of GMP Ru...

Piramal Pharma to open its new cGMP kilo lab suite in India

Piramal Pharma Solutions (PPS), a leading Contract Development and Manufacturing Organization, announced the completion of its new cGMP kilo lab suite at its API site in Ennore (Chennai, India).

Cambrex Corporation buys Avista Pharma Solutions

Cambrex, the leading manufacturer of small molecule innovator and generic APIs and finished dosage forms, announced it has entered into a definitive agreement to acquire Avista Pharma Solutions.

Israeli biopharmaceutical company receives a $10 million investment

Mapi Pharma (Israel), a privately held, fully integrated, clinical stage biopharmaceutical company has completed an equity investment of $10 million.